Gutting its R&D and clincal personnel in the middle of an FDA review. Than hire a high maintanenance sales force to sell an imaginary product. Cut corners in clinical trials because of arrogance and certaininty FDA will approve. Now, burning cash with no prospects of any foreseeable revenue in sight. This is a slow death.